A novel in vivo siRNA delivery system specifically targeting liver cells for protection of ConA-induced fulminant hepatitis
about
Update on the Pathogenic Implications and Clinical Potential of microRNAs in Cardiac DiseaseLong non-coding RNAs: critical players in hepatocellular carcinomaCombined adenovirus-mediated artificial microRNAs targeting mfgl2, mFas, and mTNFR1 protect against fulminant hepatic failure in mice.Paeoniflorin exerts a nephroprotective effect on concanavalin A-induced damage through inhibition of macrophage infiltration.miR-98 and let-7g* protect the blood-brain barrier under neuroinflammatory conditionsEffect of surface properties on liposomal siRNA delivery.New aspects of gene-silencing for the treatment of cardiovascular diseasesHepatocyte Toll-Like Receptor 5 Promotes Bacterial Clearance and Protects Mice Against High-Fat Diet-Induced Liver DiseaseA new style of dimethylnitrosamine induced fulminant hepatitis in mice.Targeted delivery of miRNA therapeutics for cardiovascular diseases: opportunities and challenges.Galactose protects hepatocytes against TNF-α-induced apoptosis by promoting activation of the NF-κB signaling pathway in acute liver failure.Synergic silencing of costimulatory molecules prevents cardiac allograft rejection.In vivo siRNA delivery of Keap1 modulates death and survival signaling pathways and attenuates concanavalin-A-induced acute liver injury in mice.Liver-specific Fas silencing prevents galactosamine/lipopolysaccharide-induced liver injury.
P2860
Q26801907-8D1BFF79-D122-4DB0-B6E9-382DD43725AEQ34685418-410C79A3-A1BD-4F26-8BA5-F029245AC59AQ35058696-88CAD7F2-2800-48AF-AE03-AB5A2867FE34Q35885340-FDA88302-B918-4B33-BE7C-8D5172BE1B3CQ36350469-D18D1BC9-48FB-43DF-B0B5-0C08AC54EA75Q36421379-919E78B6-FAE0-4E76-9D90-0B2EE3735DC9Q37277425-489B3D1C-4C8D-4D1A-A980-39847AC77654Q37297361-51C351A5-8299-420E-89B0-D884E790DD9BQ37315183-59486000-A57F-4CCC-B681-1D21D0BBE695Q38217461-0BE92131-2E5C-46B6-917C-DDA58D5C27D4Q38902209-51068467-700A-4551-929F-A3833AD09D6DQ40119079-3654D07F-B3F7-43F5-AA31-B606CCC8514AQ42837335-20C9AB21-6A47-4173-BC02-C17A40C48675Q53640671-1E981976-6C62-477E-A684-F5FE386ABC9D
P2860
A novel in vivo siRNA delivery system specifically targeting liver cells for protection of ConA-induced fulminant hepatitis
description
2012 nî lūn-bûn
@nan
2012 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
A novel in vivo siRNA delivery ...... nA-induced fulminant hepatitis
@ast
A novel in vivo siRNA delivery ...... nA-induced fulminant hepatitis
@en
A novel in vivo siRNA delivery ...... nA-induced fulminant hepatitis
@nl
type
label
A novel in vivo siRNA delivery ...... nA-induced fulminant hepatitis
@ast
A novel in vivo siRNA delivery ...... nA-induced fulminant hepatitis
@en
A novel in vivo siRNA delivery ...... nA-induced fulminant hepatitis
@nl
prefLabel
A novel in vivo siRNA delivery ...... nA-induced fulminant hepatitis
@ast
A novel in vivo siRNA delivery ...... nA-induced fulminant hepatitis
@en
A novel in vivo siRNA delivery ...... nA-induced fulminant hepatitis
@nl
P2093
P2860
P1433
P1476
A novel in vivo siRNA delivery ...... nA-induced fulminant hepatitis
@en
P2093
Douglas Quan
Guihua Chen
Hongmei Wang
Kingsun Siu
Thomas E Ichim
Vivian McAlister
Wei-Ping Min
Xiufen Zheng
P2860
P304
P356
10.1371/JOURNAL.PONE.0044138
P407
P577
2012-09-06T00:00:00Z